Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/metastatic NSCLC
Tony Mok(Chinese University of Hong Kong), Gilberto Lopes(University of Miami), Christian Caglevic, Igor Bondarenko(Dnipro State Medical University), Iveta Kudaba(Riga East University Hospital), Byoung Chul Cho(Yonsei University), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Vichien Srimuninnimit(Siriraj Hospital), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Bogusława Karaszewska(State University of Applied Sciences in Konin), Yi‐Long Wu(Guangdong Academy of Medical Sciences), H.Z. Turna(Istanbul University-Cerrahpaşa), T. Dang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kazuo Kubota(Stony Brook University), JR Penrod(Merck & Co., Inc., Rahway, NJ, USA (United States))
Cited by 39
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k